Wellington Management Group LLP Purchases 201,704 Shares of Esperion Therapeutics, Inc. $ESPR

Key Points

• Wellington Management Group LLP increased its holdings in Esperion Therapeutics by 36.0%, acquiring an additional 201,704 shares and now owning approximately 0.38% of the company valued at $1,097,000.
• Other institutional investors have also increased their stakes, with Bank of America boosting its holdings by 45.1% in the last quarter, indicating strong institutional confidence in Esperion Therapeutics.
• Esperion Therapeutics reported a quarter revenue of $82.39 million, exceeding analysts' expectations of $62.55 million, along with a narrower loss per share than anticipated.

Wellington Management Group LLP lifted its stake in Esperion Therapeutics, Inc. (NASDAQ:ESPR - Free Report) by 36.0% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 761,980 shares of the biopharmaceutical company's stock after acquiring an additional 201,704 shares during the period. Wellington Management Group LLP owned 0.38% of Esperion Therapeutics worth $1,097,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Invesco Ltd. grew its stake in shares of Esperion Therapeutics by 15.5% in the 4th quarter. Invesco Ltd. now owns 97,833 shares of the biopharmaceutical company's stock worth $215,000 after purchasing an additional 13,101 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in Esperion Therapeutics in the 4th quarter worth about $98,000. Barclays PLC boosted its stake in shares of Esperion Therapeutics by 16.0% during the 4th quarter. Barclays PLC now owns 359,235 shares of the biopharmaceutical company's stock valued at $791,000 after buying an additional 49,564 shares during the period. MetLife Investment Management LLC raised its stake in shares of Esperion Therapeutics by 65.7% during the 4th quarter. MetLife Investment Management LLC now owns 117,732 shares of the biopharmaceutical company's stock worth $259,000 after purchasing an additional 46,682 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its stake in Esperion Therapeutics by 15.3% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 123,896 shares of the biopharmaceutical company's stock valued at $273,000 after acquiring an additional 16,404 shares during the last quarter. 47.39% of the stock is currently owned by institutional investors.

Esperion Therapeutics Stock Performance

Shares of ESPR stock traded up $0.05 during trading on Thursday, hitting $2.48. The company had a trading volume of 4,218,289 shares, compared to its average volume of 4,839,909. Esperion Therapeutics, Inc. has a one year low of $0.69 and a one year high of $3.94. The firm has a market capitalization of $499.01 million, a P/E ratio of -5.05, a price-to-earnings-growth ratio of 49.87 and a beta of 0.89. The stock's 50-day moving average price is $1.60 and its 200 day moving average price is $1.35.

Esperion Therapeutics (NASDAQ:ESPR - Get Free Report) last announced its quarterly earnings data on Tuesday, August 5th. The biopharmaceutical company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.15. The business had revenue of $82.39 million during the quarter, compared to the consensus estimate of $62.55 million. Esperion Therapeutics had a negative net margin of 35.84% and a negative return on equity of 0.91%. On average, research analysts anticipate that Esperion Therapeutics, Inc. will post -0.29 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ESPR has been the subject of several research analyst reports. HC Wainwright reissued a "buy" rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Tuesday, June 17th. Wall Street Zen downgraded shares of Esperion Therapeutics from a "buy" rating to a "hold" rating in a research report on Monday, August 25th. Finally, Needham & Company LLC lowered their price target on shares of Esperion Therapeutics from $5.00 to $4.00 and set a "buy" rating for the company in a research report on Wednesday, May 7th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $7.00.

About Esperion Therapeutics

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.